Carlos Barrios, MD São Lucas Hospital Porto Allegre, RS, Brazil José Baselga, MD Vall d’Hebron Hospital Barcelona, Spain Nadia Harbeck, MD, PhD University of Cologne Cologne, Germany Cliff Hudis, MD Memorial Sloan-Kettering Cancer Center New York, New York, United States Steve Jones, MD US Oncology Houston, Texas, United States Olufunmilayo Olopade, MD, FACP University of Chicago Chicago, Illinois, United States Mark Pegram, MD University of Miami Miami, Florida, United States

Edith Perez, MD Mayo Clinic—Jacksonville Jacksonville, Florida, United States Martine Piccart-Gebhart, MD, PhD Institute Jules Bordet Brussels, Belgium Hope Rugo, MD University of California San Francisco San Francisco, California, United States Sandra Swain, MD Washington Hospital Center    Washington, DC, United States Giuseppe Viale, MD, PhD European Institute of Oncology Milan, Italy Norman Wolmark, MD Allegeny General Hospital Pittsburgh, Pennsylvania, United States

Plenary I Interview: Breast cancer biology: Is it transforming the treatment paradigm?
An overview of the management of breast cancer, with a significant focus on utilizing translational research to allow for a personalized treatment approach.

Olufunmilayo Olopade, MD, FACP
Martine Piccart-Gebhart, MD, PhD
Norman Wolmark, MD



Plenary II Interview: Early-stage breast cancer: Is it time to reassess the role of chemotherapy?
A focus on optimal treatment for hormone receptor-positive breast cancer, including the role of chemotherapy in this patient population.

Carlos Barrios, MD
Hope Rugo, MD
Sandra Swain, MD
   

Plenary III Interview: Early-stage breast cancer: How can we more precisely tailor our approach?
A focus on the evolving role of histopathology and gene expression profiles in the improved management of early-stage breast cancer.

Nadia Harbeck, MD, PhD
Edith Perez, MD
Giuseppe Viale, MD, PhD



Plenary IV Interview: Unmet needs in breast cancer: Which pathways will lead to solutions?
A focus on various unmet medical needs in breast cancer, including management of triple-negative breast cancer, targeting alternate mitogenic pathways, and optimizing the relationship between industry and academia. In addition, key points from earlier plenary sessions will be summarized.

José Baselga, MD
Cliff Hudis, MD
Mark Pegram, MD
Steve Jones, MD

This activity is intended for oncologists, surgeons, pathologists, and other practitioners involved in the care of patients with breast cancer.

The treatment of breast cancer remains a challenge for oncologists despite recent advances in the management of this heterogeneous disease. Now, in the era of molecular biology, it is important to tailor therapy for each individual patient. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific and tumor-specific considerations. While difficult, these decisions require knowledge of current clinical and experimental data in order appropriately integrate novel therapeutic agents and treatment strategies into everyday clinical practice. This educational program provides breast cancer physicians with state-of-the-art therapeutic strategies in different clinical situations in various stages of breast cancer management and the opportunity to access perspectives on the optimal treatment options discussed by renowned specialists in the field.

Upon completion of this educational activity, participants should be able to:

Plenary I Interview: Breast cancer biology: Is it transforming the treatment paradigm?

• Discuss the role of tumor biology in optimizing outcomes for patients with breast cancer
• Evaluate the importance of translational research in making treatment decisions for patients with breast cancer

Plenary II Interview: Early-stage breast cancer: Is it time to reassess the role of chemotherapy?

• Outline appropriate options for the management of endocrine-responsive breast cancer
• Discuss the role of chemotherapy in early-stage breast cancer
• Identify clinical scenarios that require chemotherapy in addition to endocrine therapy

Plenary III Interview: Early-stage breast cancer: How can we more precisely tailor our approach?

• Explain the implications of genetic analysis and biomarkers on treatment selection and response as they currently relate to patients with breast cancer

• Analyze clinical data describing various treatment strategies in order to integrate these strategies into clinical practice to improve remission and survival rates for patients with breast cancer

Plenary IV Interview: Unmet needs in breast cancer: Which pathways will lead to solutions?

• Describe the proposed mechanisms of action of new and emerging therapeutic agents for the management of breast cancer
• Evaluate new agents for the management of metastatic triple-negative breast cancer

Postgraduate Institute for Medicine assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Dr Barrios has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Baselga has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harbeck has disclosed that she has received consulting fees and fees for non-CME services from sanofi-aventis.  This relationship will not impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Hudis has disclosed that he has performed contracted research for Onyx Pharmaceuticals, Inc and MERCK & CO., Inc. Neither of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Jones has disclosed that he has received consulting fees from Amgen Inc; AstraZeneca Pharmaceuticals LP; Genentech BioOncology; GlaxoSmithKline; and sanofi-aventis. He has received fees for non-CME services from Genentech BioOncology; GlaxoSmithKline; Pfizer Inc; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Olopade has disclosed that she has no real or apparent conflicts of interest to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pegram has disclosed that he has received consulting fees from Genentech BioOncology; GlaxoSmithKline; and sanofi-aventis. He has received fees for non-CME services from AstraZeneca Pharmaceuticals LP; Genentech BioOncology; and GlaxoSmithKline. He has performed contracted research for sanofi-aventis. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Perez has disclosed that she has no real or apparent conflicts of interest to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Martine Piccart-Gebhart disclosed that she has received royalties from the American Association for Cancer Research; Clinical Publishing / Atlas Medical Publishing Ltd; PBC 2009; Wolters Kluwer; and Springer-Verlad GmbH. She has also disclosed that she has received consulting fees from Ablynx; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen, L.P.; Nordic Biotech; Onyx Pharmaceuticals Inc; Sacoor Medical Group; SCRAS Inst. Henri Beaufour. She has performed contracted research for the European Organisation for Research and Treatment of Cancer and GlaxoSmithKline. She has received salary from the European Society of Medical Oncology and Fonds Recherche Scientifique Medical. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Rugo has disclosed that she has received fees for non-CME services from AstraZeneca Pharmaceuticals. She has performed contracted research for Abbott Laboratories; Bristol-Myers Squibb Company; Genentech BioOncology; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc; and Roche Laboratories Inc. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Swain has disclosed that she has received consulting fees from Abraxis Oncology; Eisai Inc.; Genentech BioOncology; GlaxoSmithKline; ImClone Systems Incorporated; and Roche Laboratories. She has performed contracted research for Bristol-Myers Squibb and Genentech BioOncology. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Viale has disclosed that he has received consulting fees from Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; and Roche Laboratories. He has received fees for non-CME services from GlaxoSmithKline and Roche Laboratories. He has performed contracted research for GlaxoSmithKline and Novartis Pharmaceuticals Corporation. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wolmark has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


The following planners and managers of Postgraduate Institute for Medicine, Linda Graham, RN, BSN, BA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kirkwood, RN, BSN; and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following planners and managers of prIME Oncology, Amy White, RN, OCN (clinical), Trudy Stoddert, ELS (editorial), and Susan Ahn (project management) hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.